Document is current
Any future updates will be listed below
-
Authors
Dushoff, Miriam
Bowdish, Dawn M.E.
Zhabokritsky, Alice
Lovblom, Leif Erik
Klein, Marina B.
Boyachuk, Bryan
Falutz, Julian M.
Loutfy, Mona
Smith, Graham H.R.
Tan, Darrell H.S.
Cowbrough, Braeden
Walmsley, Sharon L.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (HAL 157983)
Canadian HIV Trials Network, Canadian Institutes of Health Research (CTN 314)
- License Information
-
More Information
Article History
Received: 17 September 2025
Accepted: 5 December 2025
First Online: 23 December 2025
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki, the study was approved by the University Health Network Ethics Review Board (CAPCR 18-6311) and that of the participating centers. Written informed consent was obtained from all subjects involved in the study.
: Not applicable.
: SW receives funds for investigator initiated studies, advisory board participation and lectures at CME events from ViiV Healthcare, Gilead, and Merck. She holds the Speck Family Chair in Emerging Infectious Diseases. MBK is supported by a Tier I Canada Research Chair, receives funds for investigator-initiated studies from AbbVie, Gilead and ViiV Healthcare, and consulting fees from AbbVie, Gilead and ViiV Healthcare. JMF received funds for speaker’s bureau from ViiV Healthcare, Merck, Gilead, and consulting fees from Serono. GHRS receives funds for investigator-initiated studies from ViiV Healthcare, Gilead, and Lilly. DHST’s institution has received support from Gilead for investigator-initiated research and from Gilead, GSK and ViiV Healthcare for industry-sponsored studies. All other authors report no conflict of interest to the submitted work.
